IMMUNOCORE HOLDINGS PLC-ADR Share Price Today: Live Updates & Key Insights

IMMUNOCORE HOLDINGS PLC-ADR share price today is $29.9, up -0.43%. The stock opened at $29.98 against the previous close of $30.04, with an intraday high of $30.625 and low of $29.61.

IMMUNOCORE HOLDINGS PLC-ADR Share Price Chart

IMMUNOCORE HOLDINGS PLC-ADR

us-stock
To Invest in {{usstockname}}
us-stock

IMMUNOCORE HOLDINGS PLC-ADR Share Price Performance

$29.9 -0.0043(-0.43%) IMCR at 23 Mar 2026 01:38 PM Biotechnology
Lowest Today 29.61
Highest Today 30.625
Today’s Open 29.98
Prev. Close 30.04
52 Week High 40.71
52 Week Low 23.15
Day’s Range: Low 29.61 High 30.625
52-Week Range: Low 23.15 High 40.71
1 day return -
1 Week return -2.04
1 month return -8.74
3 month return -16.54
6 month return -9.97
1 year return +0.78
3 year return -38.98
5 year return -34.82
10 year return -

IMMUNOCORE HOLDINGS PLC-ADR Institutional Holdings

T. Rowe Price Investment Management,Inc. 13.93

RTW INVESTMENTS, LLC 9.61

Wellington Management Company LLP 9.26

FMR Inc 8.95

PRIMECAP Management Company 7.82

Vanguard Health Care Inv 7.22

Bellevue Group AG 5.52

Vanguard Capital Opportunity Inv 4.99

Baker Bros Advisors LP 4.58

TANG CAPITAL MANAGEMENT LLC 4.55

T. Rowe Price US Small-Cap Core Equity 4.12

Deep Track Capital, LP 3.55

Fidelity Growth Compy Commingled Pl S 3.31

Bvf Inc 2.94

PRIMECAP Odyssey Aggressive Growth 2.40

T. Rowe Price Small-Cap Stock 2.32

Fidelity Growth Company Fund 2.30

Armistice Capital, LLC 2.17

Fiera Capital Corporation 2.06

T. Rowe Price Associates, Inc. 2.01

T. Rowe Price U.S. SC Core Eq Tr-D 1.98

Millennium Management LLC 1.80

Kynam Capital Management, LP 1.69

Logos Global Management LP 1.68

T. Rowe Price Instl Small-Cap Stock 1.35

T. Rowe Price Health Sciences 1.35

Trails Edge Capital Partners, LP 1.35

Vestal Point Capital LP 1.15

Point72 Asset Management, L.P. 1.06

Fidelity Select Health Care 0.99

Principal Financial Group Inc 0.81

T. Rowe Price US Smlr Coms Eq A 0.79

Fiera Apex SMID Growth Composite 0.72

Fidelity Select Biotechnology 0.70

Fidelity Growth Company K6 0.69

Principal U.S. Small Cap Equity 0.65

Principal U.S. Small Cap Select Equity 0.65

Principal SmallCap R5 0.64

T. Rowe Price Small-Cap Value 0.61

MFS New Discovery I 0.60

IMMUNOCORE HOLDINGS PLC-ADR Market Status

Strong Buy: 8

Buy: 5

Hold: 3

Sell: 0

Strong Sell: 1

IMMUNOCORE HOLDINGS PLC-ADR Fundamentals

Market Cap 1516.29 M

PB Ratio 3.9794

PE Ratio 0.0

Enterprise Value 1088.82 M

Total Assets 1067.27 M

Volume 278976

IMMUNOCORE HOLDINGS PLC-ADR Company Financials

Annual Revenue FY25:400016000 400.0M, FY24:310202000 310.2M, FY23:191855000 191.9M, FY22:143737000 143.7M, FY21:26520000 26.5M

Annual Profit FY25:394929000 394.9M, FY24:307471000 307.5M, FY23:190462000 190.5M, FY22:143283000 143.3M, FY21:26520000 26.5M

Annual Net worth FY25:-35514000 -35.5M, FY24:-51087000 -51.1M, FY23:-54073000 -54.1M, FY22:-41224000 -41.2M, FY21:-131523000 -131.5M

Quarterly Revenue Q4/2025:104478000 104.5M, Q3/2025:103693000 103.7M, Q2/2025:97964000 98.0M, Q1/2025:93881000 93.9M, Q4/2024:84052000 84.1M

Quarterly Profit Q4/2025:101775000 101.8M, Q3/2025:103180000 103.2M, Q2/2025:96924000 96.9M, Q1/2025:93050000 93.1M, Q4/2024:83722000 83.7M

Quarterly Net worth Q4/2025:-31022000 -31.0M, Q3/2025:785000 0.8M, Q2/2025:-10300000 -10.3M, Q1/2025:5023000 5.0M, Q4/2024:-23771000 -23.8M

About IMMUNOCORE HOLDINGS PLC-ADR & investment objective

Company Information Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Organisation Biotechnology

Employees 524

Industry Biotechnology

CEO Dr. Bahija Jallal Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

IMMUNOCORE HOLDINGS PLC-ADR FAQs

What is the share price of IMMUNOCORE HOLDINGS PLC-ADR today?

The current share price of IMMUNOCORE HOLDINGS PLC-ADR is $29.9.

Can I buy IMMUNOCORE HOLDINGS PLC-ADR shares in India?

Yes, Indian investors can buy IMMUNOCORE HOLDINGS PLC-ADR shares by opening an international trading and demat account with Motilal Oswal.

How to buy IMMUNOCORE HOLDINGS PLC-ADR shares in India?

You can easily invest in IMMUNOCORE HOLDINGS PLC-ADR shares from India by:

Can I buy fractional shares of IMMUNOCORE HOLDINGS PLC-ADR?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of IMMUNOCORE HOLDINGS PLC-ADR?

IMMUNOCORE HOLDINGS PLC-ADR has a market cap of $1516.29 M.

In which sector does IMMUNOCORE HOLDINGS PLC-ADR belong?

IMMUNOCORE HOLDINGS PLC-ADR operates in the Biotechnology sector.

What documents are required to invest in IMMUNOCORE HOLDINGS PLC-ADR stocks?

To invest, you typically need:

What is the PE and PB ratio of IMMUNOCORE HOLDINGS PLC-ADR?

The PE ratio of IMMUNOCORE HOLDINGS PLC-ADR is N/A and the PB ratio is 3.98.